Takeda's Kapidex: Can A Study On Plavix Shake Up The PPI Market?
This article was originally published in PharmAsia News
Executive Summary
Takeda could position Kapidex as the proton pump inhibitor of choice if a new clinical trial confirms its interaction profile is more agreeable than other PPI products
You may also be interested in...
BMS/Sanofi-Aventis To Study Plavix Efficacy Concerns
Genetics and concomitant PPI use are possible reasons for the anti-platelet drug’s reduced effectiveness in some patients, according to an FDA “Early Communication.”
Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review
Aetna is developing a clinical alert for physicians and pharmacists to warn about potentially reduced effectiveness for Plavix (clopidogrel) when the antiplatelet drug is used concurrently with a proton pump inhibitor, such as Prilosec (omeprazole) or Nexium (esomeprazole)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).